New supplement aims to prevent muscle loss during dieting

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has been receiving a GLP-1 receptor agonist (semaglutide) treatment for weight loss, and is titrated to start receiving a weekly dose of 1 mg semaglutide (Inclusive) * Body Mass Index (BMI): At study enrollment (participants that have achieved 1 mg titration), 25.0-34.9 (kg/m2) while receiving a GLP-1 receptor agonist (semaglutide) (inclusive) * Willing to give written informed consent to participate in the Study Exclusion Criteria: Medical History and Concurrent Diseases: * A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic/rheumatological, or oncological/hematologic disease. * Allergies related to ingredients in Study products * Known infection with HIV, TB or Hepatitis B or C. * POCBP: Not using effective contraception. Medications/Supplements: * Discontinuation of semaglutide treatment. * Discontinuation of semaglutide treatment may be necessary in some cases. However, during the titration phase, GLP-1-related symptoms often do not require treatment discontinuation or reinitiation. * Diabetes medications * Currently taking any nutritional supplements judged by the study coordinator to negate or camouflage the effects of the Study Products. See below for a brief list of explicitly allowed supplements. * Explicitly allowed supplements: Fish Oil, Multivitamin, Magnesium, Vitamin D, Vitamin C * Use of Narcotics during the last 30 days * Use of Anticoagulants during last 30 days * Use of Corticosteroids during the last 30 days Other Exclusionary Criteria: * Use of controlled substances on a recreational basis during the last 30 days. * Consumption of more than 1 alcoholic beverage per day (One beverage is a 5-ounce glass of wine, 12 ounces of beer, or one ounce of hard liquor) * Inability to comply with Study and/or follow-up visits. * Any concurrent condition (including clinically significant abnormalities in medical history, physical examination, or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance. * Any sound medical, psychiatric and/or social reason which, in the opinion of the PI, would preclude safe participation in this Study or interfere with compliance.